Skip to content

Skip to secondary menu

Jehovah’s Witnesses


Hematology (Autoimmune Diseases and Conditions)

Autoimmune Hemolytic Anemia

A case of late-onset systemic lupus erythematosus with severe anemia.

Matsumoto M, Kaieda S, Honda S, Ida H, Hoshino T, Fukuda T.

Source‎: Kurume Med J 2013;60(1):25-8.

Indexed‎: PubMed 23925156

Erythropoietin may improve anemia in patients with autoimmune hemolytic anemia associated with reticulocytopenia.

Arbach O, Funck R, Seibt F, Salama A.

Source‎: Transfus Med Hemother 2012;39(3):221-3.

Indexed‎: PubMed 22851939

Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies.

Barcellini W, Zaja F, Zaninoni A, Imperiali FG, Battista ML, Di Bona E, Fattizzo B, Consonni D, Cortelezzi A, Fanin R, Zanella A.

Source‎: Blood 2012;119(16):3691-7.

Indexed‎: PubMed 22267606

DOI‎: 10.1182/blood-2011-06-363556

Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias.

Gómez-Almaguer D, Solano-Genesta M, Tarín-Arzaga L, Herrera-Garza JL, Cantú-Rodríguez OG, Gutiérrez-Aguirre CH, Jaime-Pérez JC.

Source‎: Blood 2010;116(23):4783-5.

Indexed‎: PubMed 20841509

DOI‎: 10.1182/blood-2010-06-291831

The changing spectrum of drug-induced immune hemolytic anemia.

Arndt PA, Garratty G.

Source‎: Semin Hematol 2005;42(3):137-44.

Indexed‎: PubMed 16041663

Rituximab for the treatment of refractory autoimmune hemolytic anemia in children.

Zecca M, Nobili B, Ramenghi U, Perrotta S, Amendola G, Rosito P, Jankovic M, Pierani P, De Stefano P, Bonora MR, Locatelli F.

Source‎: Blood 2003;101(10):3857-61.

Indexed‎: PubMed 12531800

High-dose cyclophosphamide for refractory autoimmune hemolytic anemia.

Moyo VM, Smith D, Brodsky I, Crilley P, Jones RJ, Brodsky RA.

Source‎: Blood 2002;100(2):704-6.

Indexed‎: PubMed 12091370

Autoimmune hemolytic anemia.

Gehrs BC, Friedberg RC.

Source‎: Am J Hematol 2002;69(4):258-71.

Indexed‎: PubMed 11921020

Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia.

Zecca M, De Stefano P, Nobili B, Locatelli F.

Source‎: Blood 2001;97(12):3995-7.

Indexed‎: PubMed 11389047

The medical section of is designed as an informational resource primarily for use by clinicians and other health-care professionals. It provides neither medical advice nor treatment recommendations and does not substitute for an appropriately qualified health-care provider. The clinical literature cited is not published by Jehovah’s Witnesses, but it outlines transfusion-alternative strategies that might be considered. It is the responsibility of each qualified health-care provider to maintain awareness of new information, discuss options for care, and assist patients in making choices in accord with their medical condition, wishes, values, and beliefs. Not all listed strategies are appropriate or acceptable to all patients.

Patients: Always seek the advice of your doctor or other qualified health-care provider regarding medical conditions or treatments. Check with a doctor if you suspect you are ill.

The use of this website is governed by its terms of use.